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1. Introduction
Adrenocortical carcinoma (ACC) is a 
highly aggressive malignant disease with a 
high risk of recurrence even after complete 
resection and heterogeneous but gener-
ally poor prognosis in advanced stages.[1–3] 
In the majority of the cases, patients with 
ACC present with hormonal excess, mostly 
Cushing’s syndrome and symptoms of sex 
steroid excess. Patients without hormone 
overproduction generally are diagnosed 
due to symptoms of local tumor growth or 
symptomatic metastases. The therapeutic 
challenge is to both control hormone 
excess and to combat tumor progression.[4]
The only approved treatment for ACC 
is the adrenolytic drug 1,1-dichloro-2-(o-
chlorophenyl)-2-(p-chlorophenyl)ethane, 
better known by its trivial name mitotane 
(MT). MT is used both as adjuvant therapy 
after complete tumor resection and as pal-
liative treatment in case of advance disease. 
Only recently, the presumed key molecular 
mechanism of action was shown to be inhi-
bition of sterol-O-acyl transferase 1[5] but additional drug effects, 
for example, at the level of mitochondria have been reported.[6,7] 
Based on the results obtained from a large randomized phase 
III clinical trial, the combination of oral MT with intravenous 
administration of etoposide, doxorubicin, and cisplatin is cur-
rently considered as treatment standard for advanced ACC.[8,9] 
Mitotane 500 mg tablets are marketed in Europe as Lysodren 
by HRA Pharma, Paris and in the U.S. by Bristol-Myers Squibb. 
Treatment with MT is hampered by its severe side effects to the 
central nervous system (dizziness, speech difficulties, stroke-like 
symptoms), liver, and gastrointestinal tract.[10–12] While serum 
concentrations above 14 mg L−1 have been reported to be asso-
ciated with the therapeutic response,[13–16] the incidence of toxic 
effects increases beyond 20 mg L−1 leading to a narrow thera-
peutic window and the requirement of therapeutic drug moni-
toring. Management is further complicated by unfavorable phar-
macokinetic properties of MT. Even at high cumulative doses of 4 
to 6 g per day for a consecutive of 3 months, more than half of the 
patients do not achieve targeted plasma concentration.[3,17] Overall, 
MT pharmacokinetics exhibit large inter-individual variability 
which appears to be due in part due intestinal[18] and/or hepatic 
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metabolism.[19] The inactive metabolite o,p′-DDA is also found ten 
times higher in blood than the active parent compound MT.[20–22] 
The evidence that MT is strong inducer of hepatic cytochrome-
P450 enzyme further strengthens its hepatic metabolism.[23–26]
MT’s limited aqueous solubility of 0.1 mg L−1[27] is likely the 
cause of poor and variable oral absorption[28] and high volume 
of distribution.[29] Efforts in the past have been undertaken to 
shorten the time interval to reach the therapeutic serum/plasma 
concentrations and reduce the gastrointestinal side effects. Attivi 
et al. reported a self-micro-emulsifying drug delivery system 
(SMEDDS). MT was dissolved in various oils and surfactants (in 
ratio of 1:16) as individual or in the various binary and ternary 
mixtures (33% caproyl, 33% tween, and 33% cremophore EL). The 
solubility of MT in individual vehicle was maximal with 409 g L−1 
in cremophore EL. The relative bioavailability in rabbits at a dose 
of 100 mg kg−1 body weight was increased by a factor of 3.4 for 
the MT emulsion.[30] Battung and coworkers filed a patent about 
the development of an oily formulation (SMEDDS) of MT (based 
on propylene glycol monocaprylate, propylene glycol dicaprate 
and polyoxyethylene sorbitan monooleate). They were capable of 
solubilizing 0.4 g of MT per gram of oily vehicle (28 wt%). In vivo 
studies were conducted in Beagle dogs and the relative bioavail-
ability was increased by factor of 3.2 for the oily formulation.[31,32]
Lipophilicity of MT has been shown to result in predominant 
association with serum lipoproteins (LPs)[33,34] and also chyle[18] 
but only free MT was demonstrated to be therapeutically 
active.[35,36] Collectively, poor aqueous solubility and difficult to 
predict PK profile of MT are the major obstacles in MT therapy. 
Here, we aimed at the development of a novel MT nanoformu-
lations, which may enable both an injectable formulation and 
could increase bioavailability when administered orally and 
hence shorten the long lag time, which is arguably the biggest 
problem of MT in the clinics.
Micelles are formed by the self-assembly of amphiphilic 
molecules. Several polymeric micelles formulations have been 
widely studied in preclinical and clinical trials which have 
shown improved pharmacological activity and less systemic 
toxicity.[37–42] Poly(2-oxazoline)s (POx) have been discussed as 
potential biomaterial for decades but the major advancements 
have been seen in the last few years.[43,44] In particular, poly(2-
methyl-2-oxazoline)-block-poly(2-butyl-2-oxazoline)-block-
poly(2-methyl-2-oxazoline) (pMeOx-pBuOx-pMeOx) being the 
most investigated amphiphile of this polymer family has shown 
a huge potential for not only solubilizing hydrophobic drugs 
but also exhibited high cytocompatibility.[45,46] Accordingly, we 
set out to develop a novel pMeOx-pBuOx-pMeOx based MT 
nanoformulation with high drug loading. The formulation was 
comprehensively characterized and the bioactivity of the solu-
bilized MT was assessed in 2D and 3D cell culture using NCI-
H295 adrenocortical carcinoma cell line. Our results suggest 
that this novel MT nanoformulation is suitable for i.v. admin-
istration and thus may alleviate the biggest clinical problem of 
MT, its poor bioavailability and unfavorable pharmacokinetics.
2. Experimental Section
All substances for the preparation of polymer and bovine serum 
albumin (BSA) were purchased from Sigma-Aldrich (Steinheim, 
Germany) or Acros (Geel, Belgium) and were used as purchased 
unless stated otherwise. Mitotane was purchased from ISP 
chemical products, Columbus, USA. The monomer 2-n-butyl-
2-oxazoline (BuOx) was prepared according to the original pro-
cedure by Seeliger et al.[47] as modified and reported recently.[48] 
All substances used for polymerization, methyl trifluoromethyl-
sulfonate (MeOTf), 2-methyl-2-oxazoline and other solvents for 
polymer preparation were refluxed over CaH2, while benzoni-
trile (PhCN) was refluxed over P2O5 and distilled under argon. 
Deuterated solvents for NMR analysis were purchased from 
Deutero GmbH (Kastellaun, Germany). Phosphate-buffered 
saline (PBS) was prepared by dissolving 8.0 g (137 mmol) NaCl, 
0.2 g (2.7 mmol) KCl, 1.42 g (10 mmol) Na2HPO4, and 0.27 g 
(1.98 mmol) KH2PO4 in 1.0 L of deionized (DI) water (pH 7.4 at 
25 °C). If necessary, pH was adjusted to 7.4 with aqueous HCl 
or NaOH solution.
2.1. Polymer Synthesis
The polymerizations and work-up procedures were carried out 
as described previously.[48–50] As an example, the synthesis of 
A-pBuOx-A was performed as follows.
The initiator, MeOTf was added to a dried and argon flushed 
flask and dissolved in PhCN. MeOx was added and the reac-
tion mixture was heated to 110 °C for approximately 4 h. Reac-
tion progress was controlled by Fourier-transform infrared (FT-
IR) and 1H-NMR-spectroscopy. After complete consumption 
of MeOx, the mixture was cooled to RT and the monomer for 
the second block (BuOx) was added. The reaction mixture was 
heated to 120 °C and kept on stirring overnight. The procedure 
was repeated for the third block (MeOx) and after full monomer 
consumption was confirmed, termination was carried out by 
addition of 5 eq. of 1 m NaOH solution in DI water (Polymer 
batch: P1) or 3 equivalents of piperidine (Polymer batch: P2) 
at 50 °C for 4 h. Subsequently, 1 eq. of K2CO3 (only in P2) was 
added and the mixture was stirred at 50 °C for 4 h. PhCN was 
removed under reduced pressure. The highly viscous residues 
were dissolved in DI water and transferred into a dialysis bag 
(MWCO 1 kDa, cellulose acetate) and dialyzed against DI water 
for 24 h. The solution was recovered from the bag and lyophi-
lized. The products were obtained as colorless powders.
2.2. Nuclear Magnetic Resonance Spectroscopy
NMR spectra were recorded on a Fourier 300 (300.12 MHz), 
Bruker Biospin (Rheinstetten, Germany) at 298 K. The spectra 
were calibrated to the signal of residual protonated solvent 
(CDCl3 at 7.26 ppm) using MestReNova software.
2.3. Dialysis
Dialysis was performed using Spectra/Por membranes with a 
molecular weight cutoff (MWCO) of 1 kDa (material: cellulose 
acetate) obtained from neoLab (Heidelberg, Germany). DI water 
was renewed after 1, 4, and every 12 h subsequently, until the 
end of dialysis.
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2.4. Gel Permeation Chromatography
Gel permeation chromatography (GPC) was performed on an 
Agilent 1260 Infinity System, Polymer Standard Service (Mainz, 
Germany) with HFIP containing 3 g L−1 potassium trifluoro-
acetate; precolumn: 50 mm × 8 mm PSS PFG linear M; 2 col-
umns: 300 mm × 8 mm PSS PFG linear M (particle size 7 µm; 
pore size 0.1–1000 kDa). The columns were kept at 40 °C and 
flow rate was 0.7 mL min−1. Prior to each measurement, sam-
ples were filtered through 0.2 µm PTFE filters, Roth (Karlsruhe, 
Germany). Conventional calibration was performed with PEG 
standards (0.1–1000 kg mol−1) and data was processed with 
Win-GPC software.
2.5. Drug Formulation
Drug loaded polymer micelles were prepared using the thin 
film method. Ethanolic polymer (10 g L−1) and MT (10 g L−1) 
stock solutions were mixed in desired ratios. After complete 
removal of the solvent at 50 °C under a mild stream of argon, 
the films were dried in vacuo (≤0.2 mbar) for at least 30 min. 
Subsequently, preheated (37 °C) DI water, PBS, or aqueous 
serum albumin solution (40 g L−1) was added to obtain desired 
final polymer (10 g L−1) and MT concentrations. To ensure 
complete solubilisation, the solutions were shaken at 55 °C for 
15 min at 1250 rpm with a Thermomixer comfort (Eppendorf 
AG, Hamburg, Germany). Non-solubilized drug was removed 
by centrifugation for 5 min at 10.000 rpm with a 3-Speed micro 
centrifuge, (neoLab, Heidelberg, Germany). Solubilisation experi-
ments were performed with three individually prepared samples 
and results are presented as means ± standard deviation (SD).
2.6. High Performance Liquid Chromatography
HPLC analysis was carried out on a LC-20A Prominence HPLC 
(Shimadzu, Duisburg, Germany) equipped with a system con-
troller CBM-20A, a solvent delivery unit LC-20 AT (double 
plunger), an on-line degassing unit DGU-20A, an auto-sampler 
SIL-20AC, a photo diode array detector SPD-M20A. As sta-
tionary phase, a ZORBAX Eclipse Plus (Agilent, Santa Clara, 
CA, USA) C18 column (4.6 mm × 100 mm; 3.5 µm) was used. 
Quantification of MT was performed with a stepwise gradient. 
Within the first 10 min, the ratio of H2O/ACN was decreased 
from 60/40 (v/v) to 40/60 (v/v). Solvent ratio was kept constant 
for 5 min, prior to increasing it to the initial ratio of 60/40 (v/v) 
within 0.5 min. This ratio was kept for 5 min. Flow rate was 
1 mL min−1. Detection was performed at 230 nm and the reten-
tion time was 3.9 min.
2.7. Loading Capacity and Loading Efficiency
The following equations were used to calculate the loading 













where mdrug and mexcipient are the weight amounts of the solu-
bilized drug and polymer excipient in solution and mdrug,added 
is the weight amount of the drug initially added to the 
dispersion. No loss of polymer during micelles preparation 
was assumed.
2.8. Long Term Stability Studies
For long term stability studies, formulated MT was stored at 
ambient conditions (≈25 °C) under the exclusion of light. The 
samples were collected at day 0, 1, 2, 3, 4, 5, 10, 20, and day 30. 
Before the determination of the drug loading by HPLC, all sam-
ples were centrifuged for 5 min at 10 000 rpm with a 3-Speed 
micro centrifuge (neoLab, Heidelberg, Germany). Long-term 
stabilization experiments were performed with three individu-
ally prepared samples and results are presented as means ± SD, 
quantification was carried out as described above.
2.9. Redispersion Studies
The freshly prepared formulations were frozen in liquid 
nitrogen and subjected to 24 h lyophilization to obtain the 
dried powdered MT formulation for redispersion studies. 
The media used for the redispersion (keeping the polymer 
concentration 10 g L−1) were DI water, cell culture medium, 
PBS, and PBS with 40 g L−1 BSA. The formulations were 
shaken at 1250 rpm with a Thermomixer comfort (Eppendorf 
AG, Hamburg, Germany) at room temperature for 10 min 
followed by HPLC analysis as stated in section long-term 
stability studies.
2.10. Polymer Drug Compatibility Evaluation by 
Hansen Solubility Parameters
The extent of compatibility between MT and the core forming 
block of the ABA triblock copolymers was calculated by 
employing the Hildebrand–Scatchard equation:[51]




( )drug polymer drug polymer
2  (1)
where χdrug−polymer (χdp) is Flory–Huggins interaction parameter, 
δdrug and δpolymer are the total solubility parameter (δtotal) for the 
MT and the core forming block, respectively. V is the molar 
volume of MT calculated by Fedors methods,[52] while R is the 
gas constant and T is the temperature. The δtotal (also called as 
3D solubility parameter) that is, δdrug and δpolymer were further 
calculated by following equations:
d p hdrug
2 2 2 2δ δ δ δ= + +  (2)
d p hpolymer
2 2 2 2δ δ δ δ= = +  (3)
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The δtotal is the sum of dispersion (δd), polar (δp), 
and hydrogen bonding forces (δh). The δd, δp, and δh were 
further calculated by Hoftyzer and Van Krevelen’s addi-















hiδ = Σ  1/2  (6)
where Fdi, Fpi, and Ehi are the molar dispersion, polar attrac-
tion constant and hydrogen bonding energy, respectively. Each 
structural group in the molecule contributes towards the Fdi, 
Fpi, and Ehi.
2.11. Fourier Transform Infrared Spectroscopy
The FT-IR spectra were recorded on a FT-IR-4100 (Jasco, Gross-
Umstadt, Germany), measuring from 500 to 4000 cm−1. The 
aqueous MT formulations were lyophilized to obtain the dry 
powdered formulation prior to FT-IR measurements.
2.12. Differential Scanning Calorimetry
For DSC studies samples were placed into flat-bottom 
aluminum pans with the pierced lids. The aqueous MT formu-
lations were lyophilized to obtain the dry powdered formulation 
prior to DSC measurements.
DSC was performed on DSC 204 F1 Phoenix equipped 
with a CC200 F1 Controller, (NETZSCH, Selb, Germany). The 
dynamic scans were recorded in nitrogen atmosphere with a 
heating rate of 10 K min−1 (25–200 °C) and subsequently cooled 
to −50 °C (10 K min−1). The samples were heated and cooled 
two additional times from −50 to 200 °C (10 K min−1) (three 
heating and two cooling cycles).
2.13. X-Ray Diffraction
Powder X-ray diffraction (XRD) was performed at STADI P 
from STOE (STOE & Cie GmbH, Darmstadt Germany). The 
setup is equipped with radiation source of Cu-Kα and the 
detector is linear PSD. Measurement were done at 0.15° steps 
each step lasting 180 s in transmission mode at 40 kV voltage 
and 30 mA current and 2ϴ angle ranging from 5° to 60° were 
used.
2.14. Dynamic Light Scattering
Dynamic light scattering were measured on Zetasizer Nano 
ZSP from Malvern, (Malvern Instruments, Worcestershire, 
UK) in disposable cuvettes (UV cuvettes semi micro, BRAND 
GmbH, Wertheim, Germany) at ambient temperatures 
(≈25 °C). Data was analyzed by using zetasizer software 7.11. 
All the samples were measured after filtration using 0.45 µm 
PVDF syringe filter (Rotilabo, Karlsruhe). The filtered samples 
were further diluted (1:1 ratio with DI water) and measured 
again to exclude variation due to dilution effect (Figure S11, 
Supporting Information). The measurements were recorded 
as average of three test runs for two individually prepared 
samples.
2.15. Cell Culture
The adherent adrenocortical cell line NCI-H295R (ATCC, 
USA)[53] and HepG2 cell line (ATCC, USA) were grown in 
DEMEM/F-12 1:1 mix (Gibco, USA) supplemented with 1% 
insulin-transferrin-selenium (Gibco, USA) and 3% Nu-Serum 
(Corning, USA). Cells were cultured at 37 °C and 5% CO2 
humid atmosphere in flasks.
2.16. Monolayer Culture and Spheroid Formation
For monolayer cell culture, 1 × 105 cells were seeded in a flat 
bottom 96-well plate in 100 and 200 µL medium for cytocom-
patibility studies and cytotoxicity studies, respectively, and 
incubated for 24 h. For spheroid formation 5 × 104 cells were 
seeded in 96-well plates, coated with 50 µL 1.5% autoclaved 
agarose (Sigma-Aldrich, Germany) in a total volume of 200 µL 
culture medium. Initially, the spheroid formation was induced 
by centrifugation at 1 g for 3 min. Medium was refreshed after 
48 h by exchanging 100 µL of supernatant. After 96 h spheroids 
were formed in each well.
2.17. Cytocompatibility Studies
The cytocompatibility studies of the polymer alone (both 
polymer batches, P1 and P2) were performed on monolayer 
culture of HepG2 cell line and NCI-H295R. The cells were 
cultured as stated, after 24 h incubation the monolayers were 
exposed to various polymer concentrations, that is, 1, 5, 10, 
25, 50, and 100 g L−1 (prepared in cell culture medium). 
Treated plates were incubated for 6 and 24 h. Cell viability 
was assessed by WST1 (NCI-H295R and HepG2 cells) and 
cellTiter-Glo-3D-assay (Promega, Germany) (NCI-H295R). 
Briefly, after the incubation time of 6 and 24 h the treated 
plates (with HepG2 cells) were exposed to WST1 reagent 
(10 µL in each well). The plates were further incubated for 
2 h followed by the absorbance measurement by multilabel 
plate reader Wallac Victor 1420 (PerkinElmer, USA). CellTiter-
Glo-3D assay was performed according to the manufacturer’s 
instructions. 150 µL of supernatant was removed and replaced 
with 50 µL of CellTiter-Glo-3D-Reagent. Cell lysis was induced 
by mixing with multichannel pipettes and the lysate was trans-
ferred to opaque plates. After 25 min of incubation lumines-
cence was measured by multilabel plate reader Wallac Victor 
1420 (PerkinElmer, USA).
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2.18. Cytotoxicity Studies in 2D and 3D Cell Spheroids
The efficacy of MT formulated in micelles or MT dissolved in 
EtOH was comparatively assed in 2D cell culture and 3D cell 
spheroids. Mitotane treatment was performed after 24 h of 
culturing for monolayer and 96 h for spheroids culture in a 96 
well-plate, by removing 100 µL medium and adding 100 µL cul-
ture medium containing either mitotane-EtOH or mitotane in 
micelles to attain final concentrations ranging from 5 to 75 µm 
and 50 to 200 µm for monolayer and spheroids, respectively. 
Various stock solutions of mitotane in micelles (2 mm stock 
solution, prepared in cell culture medium) and mitotane-EtOH 
(MT was dissolved in absolute ethanol in 500–20 mm stock 
solutions) were prepared. Stocks solutions were further diluted 
with cell culture medium to obtain final concentrations. EtOH 
concentration was 1% (v/v) in all mitotane-EtOH samples and 
controls. Treated plates were incubated for 24 and 48 h. All 
experiments were performed in triplicate with n = 8 in each 
replicate, unless specified otherwise.
2.19. Statistical Analysis
Statistical analysis was performed using two-way ANOVA using 
GraphPad prism software version 5.01. Statistical significance 
was calculated by applying Bonferroni post hoc tests.
3. Results and Discussions
3.1. Polymer Synthesis and Characterization
Block copolymers of POx are easily accessible by living cationic 
ring-opening polymerization (LCROP) and POx amphiphiles 
are highly tunable with respect to solubility, size, architecture 
as well chemical functionality.[54–57] All polymers in this study 
were also synthesized by LCROP using methyltriflate as an 
initiator (MeOTf) as previously described.[48,50] All ABA tri-
block copolymers comprised hydrophilic pMeOx as block A and 
poly(2-n-propyl-2-oxazoline) (pPrOx), poly(2-n-propyl-2-oxazine) 
(pPrOzi), poly(2-n-butyl-2-oxazoline) (pBuOx), poly(2-benzyl-
2-oxazoline) (pBzOx), and poly(2-n-butyl-2-oxazine) (pBuOzi) 
as hydrophobic block B, respectively (Table 1). Two polymer 
batches of pBuOx based triblock copolymer (P1 and P2) were 
synthesized specifically for this contribution and terminated 
with NaOH/water and piperidine, respectively. In our previous 
work, we have observed relatively minor effect of the polymer 
termini in poly(2-oxazoline)/poly(2-oxazine) (POx/POzi) based 
ABA triblock copolymers, but this may have to be assessed on a 
case-by-case basis.[46,58] Both batches were characterized by 1H-
NMR and GPC. A satisfactory synthetic control was achieved 
in both batches of the polymer, supporting the excellent repro-
ducibility for this polymer synthesis.[59] For further analytical 




POx-based amphiphiles have tremendous potential for for-
mulation development.[45,58,60,61] For example, Milonaki et al. 
reported very high drug loading with indomethacin using an 
(pseudo-diblock) copolymers from 2-methyl-2-oxazoline and 
2-phenyl-2-oxazoline.[61] Luxenhofer et al.[58] reported the ultra-
high paclitaxel (PTX)-loaded POx-based micellar formulation 
with very promising in vivo data. The lead amphiphile is a ABA 
triblock copolymer, A and B being comprised of hydrophilic 
poly(2-methyl-2-oxazoline) (pMeOx) and modestly hydrophobic 
poly(2-butyl-2-oxazoline) (pBuOx), respectively (pMeOx-pBuOx-
pMeOx). The loading capacity (LC) was found to be 50 wt% cor-
responding to an increase of solubility of PTX over five order of 
magnitude to 50 g L−1. PTX/POx formulation showed superior 
antitumor efficacy with the maximum tolerated dose (MTD) of 
150 mg kg−1 when compared to commercially available formu-
lations, that is, Taxol and Abraxane (MTD being 20 and 90 mg 
kg−1, respectively).[60] Wan et al. recently reported the co-formu-
lation of etoposide (ETO) and a hydrophobized cisplatin (Cis) 
using the similar amphiphile (pMeOx-pBuOx-pMeOx). This 
co-formulation demonstrated superior antitumor efficacy on 
various small cell and non-small cell lung cancer models as 
compared to single drug micelles or their combination as well 
as free drug combination.[62]
It is an usual assumption that the hydrophobic block is 
mainly responsible for solubilisation of hydrophobic drugs and 
that increasing the hydrophobicity of the core forming block 
(B) can increase the solubilisation capacity of an amphiphile. 
More recently, more specific interactions between polymers 
and their cargo have come into the focus of researchers.[63,64] 
In the case of POx-based amphiphiles an inverse relationship 
between the hydrophobicity of the micellar core and the drug-
loading capacity has been observed repeatedly. Lübtow et al.[49] 
have recently reported a study on this behavior showing that 
POx- and POzi-based ABA triblock copolymer with long linear 
or branched side chains, that is (poly(2-nonyl-2-oxazoline) 
(pNonOx) or (poly(2-(3-ethylheptyl)-2-oxazoline) (pEtHepOx) 
rather negatively affect the LCs for hydrophobic drugs, cur-
cumin (CUR) and PTX. Besides higher solubilizing capacity of 
short side chain core forming blocks, Lübtow et al.[48] further 
reported that minor changes in the chemical structure of short 
side chain core forming blocks, that is, a formal transition of 
one methylene unit from side chain (pBuOx) to the back bone 
Macromol. Biosci. 2020, 20, 1900178
Table 1. Physicochemical characterization of all the polymers used in 
this study including the molecular weight Mn and dispersity Ð.
Polymer Mna) [kg mol−1] Mnb) [kg mol−1] HFIP Ð
b)
A41-pPrOx23-A40 9.7 4.7 1.19
A35-pPrOzi20-A35 8.7 5.4 1.19
A33-pBuOx20-A33 (P1) 8.1 3.6 1.10
A32-pBuOx20-A32 (P2) 8.0 5.6 1.10
A40-pBzOx20-A41 10.3 5.2 1.25
A35-pBuOzi20-A35 9.0 5.6 1.20
a)obtained by 1H-NMR analysis (CDCl3; 300 MHz); b)obtained by GPC analysis 
(eluent: HFIP, PEG calibration). The values are taken from the refs. [48,50].
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(pPrOzi) or introduction of aromatic moieties[50] have signifi-
cant impact on the LCs for hydrophobic drugs, indicating very 
strong polymer/drug specificities.
Accordingly, the solubilization of MT, which exhibits an 
extremely low water solubility,[27] zero H-bond donor groups, 
and higher aromatic character, was tested using five different 
ABA triblock copolymers including the most commonly inves-
tigated ABA triblock amphiphile, that is, A-pBuOx-A, and 
A-pPrOzi-A, A-pBuOzi-A, A-pPrOx-A, and A-pBzOx-A (Figure 1c 
and Table 1). The polymers with short linear side chain (which 
have been shown to optimally solubilize various hydrophobic 
drugs)[48,58] or with the aromatic content (inspired by a potential 
benefit of π-π stacking between drug and carrier)[50,65,66] were 
specifically selected to find a good MT solubilizer, for which 
only very few formulations are reported to date.[30,67] Using 
the thin-film approach (Figure 1b), we prepared micellar for-
mulations of MT with the aforementioned amphiphilic triblock 
copolymers (Table S1, Supporting Information). Briefly, the 
polymer and MT were dissolved in ethanol, which was subse-
quently removed and the resulting thin-film was dissolved by 
adding DI water. We kept the targeted polymer concentration at 
10 g L−1 and increased the targeted MT concentration from 2 to 
10 g L−1. The actual MT concentration achieved in the aqueous 
phase was assessed using HPLC (Figure 2a) after removal of 
non-solubilized drug.
Increasing the MT feed from 2 to 10 g L−1 raised the LC 
from 11 to 36 wt% (1.25 and 5.7 g L−1, respectively) (Table S1–
S3, Supporting Information). A-pBuOx-A being the best solu-
bilizer for PTX,[58] also gives the highest MT loading among 
the tested amphiphiles. Up to 6 g L−1 (19 mm) MT could be 
obtained as a clear micellar solution with low viscosity (LC = 
36 wt%). Therefore, the apparent solubility could be increased 
by a factor of 6 × 104. Notably, the loading efficiency (LE) did 
not change much while increasing the MT feed from 2 to 10 g 
L−1, ranging between 55% and 75%. As stated previously, from 
a physiological perspective one possibility could be that, MT 
upon oral administration, because of its strong association to 
lipoproteins, enters the lipid transport pathway and MT bound 
to chylomicrons or their remnants are repeatedly exposed to 
hepatocytes resulting in higher rate of biotransformation and 
a much higher inactive metabolite concentration in blood. We 
postulate the administration of MT injectable formulation will 
render the optimal MT active metabolite concentration in blood 
by reducing its hepatic and extra hepatic metabolism. To the 
best of our knowledge, such high apparent MT aqueous solu-
bility was never reported in the literature. Formulation experi-
ments were performed with both polymer batches (P1 and P2) 
and no significant difference was observed in loading capacities 
(Tables S2 and S3, Supporting Information). In comparison to 
A-pBuOx-A, A-pBuOzi also gave good, somewhat lower LC of 
27 wt% (≈3.7 g L−1). In contrast, A-pPrOzi-A and A-pPrOx-A 
were much less effective in solubilizing MT with LC of 10 wt% 
(≈1.3 g L−1) and 5 wt% (≈0.5 g L.) respectively. Also, the aro-
matic A-pBzOx-A was found less efficient than expected[50] but 
was slightly better than A-pPrOx-A and A-pPrOzi-A with LC 
≈16 wt% (≈2 g L−1) (Table S1, Supporting Information). Based 
on these results, we chose A-pBuOx-A based MT formulations 
for detailed physicochemical characterization and biological 
studies.
3.2.2. Stability and Redispersion Studies of the Formulation
To investigate the potential shelf-life of the formulations 
(A-pBuOx-A), the freshly prepared MT aqueous solutions were 
stored at ambient conditions containing the initial precipitate 
followed by the collection of samples at day 0, 1, 2, 3, 4, 5, 
and then at day 10, 20, 30. The formulations were centrifuged 
prior to each measurement. We have previously observed PTX-
based A-pBuOx-A formulations have shown excellent stability 
up to several months[45,68]; however, other POx/PTX formula-
tions were much less stable.[69] The formulations with the MT 
feed of 2 and 4 g L−1 resulted in relatively stable formulations 
(Figure 2b). After 24 h only a minor loss in the LC was observed 
in both cases (11 to 10 wt% and 22 to 21 wt%, respectively). 
However, after 30 days, the LC decreased to 3 and 10 wt%, 
respectively. In case of higher MT feed of 6, 8, and 10 g L−1 
(Figure 2b) a dramatic decrease in the LC (30 to 3, 35 to 2, 
and 36 to 4 wt%, respectively) was observed within 24 h. It is 
becoming more and more evident that drug molecules can also 
Macromol. Biosci. 2020, 20, 1900178
Figure 1. a) Schematic representation of the polymers used in this this study. b) Chemical structure of Mitotane and c) schematic illustration of thin 
film hydration method for formulation development.
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coordinate with the micellar corona.[70,71] This drug–corona 
interaction can enable to ultra-high drug loading[71,72] or lead 
to colloidal instability of the formulation.[49,73] However, the 
drug corona interaction can also affect the morphology,[74] 
endocytosis,[75,76] or prolong supersaturation.[77] Interestingly, 
for the POx/POzi nanoformulations the drug was found fully 
amorphous in the precipitate, which also contains polymer.[49,70] 
It therefore appears that the micelles agglomerate and precipi-
tate with the still amorphous drug embedded. However, the 
extremely rapid precipitation observed here at polymer/drug 
feed ≥10/6 g L−1 suggests at a different mechanism. Therefore, 
we investigated the precipitate after 24 h from a formulation 
with polymer/drug feed of 10/8 g L−1 by differential scanning 
calorimetry (DSC). The first heating cycle clearly showed the 
melting peak of MT at 78 °C (Figure S10, Supporting Informa-
tion), indicative of MT rapid crystallization from the formula-
tion above a critical feed of >10/4 g L−1. In contrast, at 10/4, 
A-pBuOx-A acts as a rather effective crystallization inhibitor. 
This could be very promising for improving the bioavailability 
after oral administration.
Formulations with limited stability in an aqueous environ-
ment may be stored in lyophilized state. In this case, redispers-
ibility is a key issue. Here, the A-pBuOx-A based MT formula-
tion with the drug feed of 2 and 4 g L−1 were lyophilized and 
redispered in different media (Figure 2c,d). The lyophilized 
formulations were stored for 7 days at ambient conditions 
followed by redispersion in DI water, cell culture medium, PBS 
and PBS with 40 g L−1 BSA. Upon redispersion with DI water, 
initially a minor decrease in LC (11 to 10 and 22 to 18 wt% for 
2 and 4 g L−1 MT feed, respectively) was observed. A similar 
pattern was observed in case of other redispersion mediums. 
However, long-term stability after redispersion followed a sim-
ilar pattern as that for freshly prepared formulation showing 
time dependent gradual decrease in LC. It can be concluded 
that A-pBuOx-A based MT formulations should be stored as 
lyophilized powder and used freshly after redispersion. Even 
though this was not systematically studied at this point, the lyo-
philized powders seem to be quite stable at ambient conditions. 
No deterioration of re-dispersibility was observed over the time 
course of this study. Of course, these preliminary studies to not 
exclude the possibility to extend shelf-life, for example, by addi-
tion of other excipients.
3.2.3. Polymer Drug Compatibility Evaluation by Hansen Solubility 
Parameters
The physicochemical compatibility between an active pharma-
ceutical ingredient and the drug delivery system is believed 
to be a key factor in the formulation development process 
Macromol. Biosci. 2020, 20, 1900178
Figure 2. a) Maximum aqueous mitotane concentration obtained using different amphiphilic block copolymers (10 g L−1) using the thin film method. 
Data is given as means ± SD (n = 3) only for A-pBuOx-A based formulation. b) Long term stability of mitotane formulation in dependence of mitotane 
feed concentration (polymer 10 g L−1, mitotane 2–10 g L−1). Data is given as means ± SD (n = 3). Formulation stability after redispersion of A-pBuOx-
A: mitotane c) polymer to mitotane feed ratio of 10/2 and d) 10/4 formulation in different media, that is, deionized (DI) water, cell culture medium, 
phosphate buffer saline (PBS) of pH 7.4 and PBS of pH 7.4 with 40 g L−1 bovine serum albumin up to day 30.
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to determine the suitability of the drug delivery system. 
Considering the plethora of drugs with unique physicochem-
ical properties, a universal carrier for all the drugs seems 
impossible.[78] There are various ways to assess the drug 
poly mer compatibility[79–82] which are thought to help to select 
a suitable carrier for a specific drug in time and cost effec-
tive manner. The extent of compatibility between MT and 
POx based carriers was calculated by the Hansen solubility 
parameter (HSP) (Table 2).[83,84] For the further details on 
HSPs calculations please refer to the Supporting Information 
(Tables S4–S5, Supporting Information).
The extent of compatibility between MT and the core forming 
blocks was estimated by Flory–Huggin’s interaction parameters 
(χdp). The lower the value of χdp the better the polymer/drugs 
compatibility. Based on the calculated χdp, MT compatibility 
with five of selected amphiphiles was in the following order 
pBuOx=pPrOzi > pBuOzi > pPrOx > pBzOx. Interestingly, the 
core forming block pBuOx and pPrOzi are suggested to be 
best solubilizers for the MT. Being based on group contribu-
tion methods, the calculated solubility parameters of pBuOx 
and pPrOzi, which are structural isomers, yielded identical 
solubility parameter values and thus, compatibility for the drug 
MT. Experimentally, however, strong contrast in the solubiliza-
tion capacities were found, similar to the situation reported for 
other drugs.[48] Interestingly, pBzOx was suggested to be the 
least compatible polymer, even though it features the aromatic 
system. It is apparent that the experimental results are only 
partially consistent with the calculated compatibility profile 
between MT and core forming blocks. It seems that the correct 
assignment of the best solubilizer, pBuOx is more coincidental 
and does not indicate that HSP can correctly predict compat-
ibilities in the present system.
3.2.4. Physicochemical Characterization of MT Nanoformulations
A-pBuOx-A based MT nanoformulations were characterized 
using FT-IR, DSC, XRD, and DLS (polymer/drug 10/2 g L−1). 
FT-IR spectroscopy (Figure 3a) of lyophilized formulation in 
comparison with the physical mixture, pure drug, and pure 
polymer was performed to characterize potential interac-
tions between MT and polymer. Pure MT is characterized 
by a number of sharp signals, with particular strong signals 
in the range of 700–800 cm−1, which are attributed to the 
CCl stretching vibration. MT also exhibited a characteristic 
signal at 1490 cm−1, which is attributed to CC aromatic 
stretch. While in the physical mixture these signals can still 
be observed, they completely vanished in the case of nanofor-
mulation. The broader signal at 1630 cm−1 is attributed to the 
stretching and bending vibration of carbonyl stretch and no 
noticeable change was observed between the spectra of physical 
mixture and nanoformulation. Overall, IR suggest very signifi-
cant interaction between MT and the polymer. As the sharp sig-
nals of MT do not shift but significantly broaden to the point of 
becoming indiscernible these interactions are presumed to be 
versatile and undefined.
In order to investigate the thermal behavior of MT nanofor-
mulations, DSC (Figure 3b) was conducted for pure polymer, 
pure drug, physical mixture, and the lyophilized nanoformula-
tion. The thermogram of pure drug and its physical mixture 
with polymer showed an endothermic peak at 80 and 78 °C, 
respectively, which represents the characteristic melting peak of 
MT. The disappearance of the melting endothermic peak of the 
drug in the nanoformulation shows that MT is fully amorphous 
in the lyophilized nanoformulation. Therefore, the lyophilized 
nanoformulation can be considered a solid amorphous disper-
sion of MT in A-pBuOx-A.
For further analysis, pure polymer, pristine drug, physical 
mixture, and the lyophilized micellar formulation were ana-
lyzed by powder-XRD (Figure 3c). The XRD spectra of the pris-
tine MT shows numerous reflexes in the 2ϴ range of 5 to 40° 
corresponding to the crystalline nature of MT. The identical 
spectrum was observed for physical mixture of drug with pol-
ymer. In contrast, no signs of crystallinity were observed in case 
of lyophilized nanoformulation even after 15 days of storage at 
ambient conditions, confirming the amorphous nature of MT 
Macromol. Biosci. 2020, 20, 1900178
Table 2. Hansen solubility parameters of mitotane and core forming 
blocks of the ABA triblock copolymers.






pPrOx 20.1 12.3 8.8 25.1 90.2 0.327
pPrOzi 19.6 10.4 8.1 23.6 106.3 0.009
pBuOx 19.6 10.4 8.1 23.6 106.3 0.009
pBzOx 22.8 10.0 7.9 26.1 112.0 0.750
pBuOzi 19.2 9.1 7.6 22.5 122.4 0.055
Mitotane 18.7 9.2 2.6 21.0 240.8
a)Calculated by Hoftyzer and Van Krevelen’s method, Equations (4), (5), and (6); 
b)calculated by Equations (2) and (3); c)calculated by Fedor’s method; d)calculated 
by Equation (1).
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in the nanoformulation. After redispersion, the hydrodynamic 
radii (Rh) of the micelles was estimated by zeta sizer (Figure 3d 
and Figure S11, Supporting Information) showing Rh ≈ 40 nm 
for the pure polymer and Rh ≈ 20 nm for the MT-encapsulated 
micelles.
3.3. Cell Studies
3.3.1. Cytocompatibility Studies on HepG2 and NCI-H295 
Cell Lines
When it comes to the in vivo administration, the safety of the 
polymer excipients is of great interest. Even though cytocom-
patibility of POx based amphiphiles has been established sev-
eral times,[46,58,85] cytocompatibility of the presently employed 
polymer was investigated in HepG2 and NCI-H295 cell lines 
using WST1 and CellTiter Glo assay (which reflects ATP con-
tent) after treatment with polymer solution at different con-
centrations for 6 and 24 h. We investigated both polymer 
batches, that is, P1 and P2 by WST1 assay in NCI-H295R and 
HepG2 cell lines at concentrations of up to 100 and 50 g L−1 
for P2 and P1, respectively (Figure 4a,b and Figure S12, Sup-
porting Information). No sign of cytotoxicity was observed 
and cell viability remained above 95% in all cases indicating 
its excellent cytocompatibility. Similar results were obtained 
using the CellTiter Glo assay (Figure 4c and Figure S12, Sup-
porting Information).
3.3.2. In Vitro 2D and 3D Cytotoxicity Studies of Nanoformulations 
on NCI-H295 Cell Lines
The cytotoxicity of MT in EtOH and micellar formulation was 
determined by CellTiter Glo assay in both 2D (monolyer) and 
3D (spheroids) NCI-H295R cell lines, for 24 and 48 h. In all the 
cases dose dependent cytotoxicity was observed.
For the monolayer culture, there was no significant differ-
ence in cytotoxicity between MT in EtOH and MT in micelles 
(p > 0.05) upon 24 h incubation (Figure 5a). The IC50,24h were 
15 and 19 µm for MT in EtOH and micelles, respectively, which 
corresponds well with values found in the literature (IC50,24h = 
15 µm.[18] The cell viability was less than 3% at 50 µm MT 
concentration (either in EtOH or micelles) consistent with the 
previous reports by Silveira et al. and others.[86,87] Prolonged 
incubation had no effect on IC50 values (IC50,48h = 15 and 18 µm 
for MT in EtOH and micelles, respectively (p > 0.05), Figure 5b).
There is growing evidence that cancerous cells grown as 
spheroids do more accurately mimic the 3D tumor micro-
environment when compared to monolayer cultures.[88] Besides 
Macromol. Biosci. 2020, 20, 1900178
Figure 3. a) FT-IR spectra, b) DSC thermograms (first heating cycle for drug, mixture, formulation, and second heating cycle for pure polymer is shown) 
and c) XRD spectra of pure drug (black), polymer (red), physical mixture of drug, and polymer (blue) and nanoformulation (purple) for a polymer to 
drug ratio 10/2 (w/w). d) The size distribution by intensity of pure polymer (10 g L−1) (red) and mitotane formulation (10/2 w/w) (purple) in deionized 
water after filtration through 0.45 µm PVDF filter.
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activation of cell–cell and cell–matrix interactions, spheroids 
also simulate some in vivo tumor characteristics such as dor-
mancy, hypoxia, and activation of anti-apoptotic signaling. After 
96 h of incubation, we obtained single, uniformly sized, and 
dense spheroids of NCI-H295R cells (Figure S14, Supporting 
Information).[87] In general, when compared to 2D monolayer 
cells, cancer cells are less sensitive to drugs when analyzed in 
spheroids. This could be attributed to hypoxia and tight cell–
cell interactions in spheroids leading to poor permeability, 
among other factors.[89] Accordingly, we used range of higher 
concentration (50 – 200 µm MT). Important to note, the MT 
in EtOH dilution (prepared in cell culture medium) at 200 µm 
turned milky, whereas A-pBuOx-A based MT micelles remained 
a clear solution. This suggests MT emulsion or precipita-
tion and it follows that such high concentrations are feasible 
in vivo only when using a suitable drug carrier. In spheroids, 
we expectedly observed resistance to pharmacotherapy with 
IC50,24h values determined at 75 and 65 µm for MT in EtOH 
and micelles, respectively (Figure 5c), whereas IC50 was 15 
and 19 µm in monolayer cultures. Cell viability was drastically 
reduced at 100 µm (<30%) and 150 µm (<7%) MT concentra-
tion either in ethanol or micelles. Almost no cells survived at 
200 µm MT concentration (Figure 5c), irrespective whether MT 
was administered in EtOH or as nanoformulation.
Interesting to note, in case of spheroids, incubation time did 
affect cell viability. The IC50,48h was found to be 47 and 43 µm 
for MT in ethanol and micelles, respectively (Figure 5d). Data 
reported by Silveira et al. suggest that 72 h incubation time of 
NCI-H295 cell spheroids[87] led to 15 and 26% cell viability at 
30 and 50 µm MT concentration (dissolved in ethanol), respec-
tively. However, it is possible that different strains of NCI-H295 
cells and culture conditions may affect the properties of sphe-
roids cultivated in different laboratories.
When comparing the increase of IC50 values from 2D mono-
layer cultures to 3D spheroids we observed a more pronounced 
increase of IC50 values for MT in EtOH compared to our nano-
formulation. At 24 h incubation, the increase was fivefold when 
using EtOH but only 3.4-fold in case of the nanoformulation. At 
48 h, the IC50 values increased 3.1 (EtOH) and 2.4 (A-pBuOx-A) 
fold. This could potentially be attributed to a better penetration 
of the drug into the spheroids when nano formulated, but this 
hypothesis will need to be tested thoroughly.
4. Conclusion
Motivated by the poor aqueous solubility (0.1 mg L−1), extremely 
high daily dosage (up to 6 g per day in divided doses) and unfa-
vorable pharmacokinetic profile of the adrenolytic drug mitotane 
(MT), we attempted the development of MT loaded micelles 
which may enable both improved oral administration and an 
injectable formulation to overcome critical clinical limitations. 
A poly(2-oxazoline) (POx) based formulation (pMeOx35-pBuOx20-
pMeOx35) was capable to increase the aqueous solubility of MT 
to around 6 g L−1 (LC ≈ 36 wt%). To the best of our knowledge, 
such high MT water solubility has never been reported in the 
literature. Various instrumental techniques confirmed the devel-
opment of a stable nanoformulation. This formulation can be 
stored as lyophilized powder ready for re-dispersion. The pol-
ymer excipient was proven to be highly cytocompatible even at 
extremely high concentrations of 100 g L−1 in NCI-H295R and 
HepG2 cell lines (cell viability > 95%). The obtained IC50 values 
in conventional 2D monolayer cell cultures were comparable for 
MT dissolved in EtOH and micelles (15 and 19 µm, respectively) 
while in the case of 3D tumor spheroids higher doses were 
needed to obtained cytotoxic effects, which confirms an increased 
resistance of the tumor cells cultured in 3D. The IC50 at 24 h 
values were 75 and 65 µm for MT in EtOH and micelles, respec-
tively. Time dependent decrease in IC50 after 48 h incubation was 
observed in case of spheroids (47 and 43 µm for MT in EtOH and 
micelles, respectively) which points to a diffusion limited process 
of tissue penetrance. It stands to reason that this nanoformula-
tion, for the first time, might allow the parenteral administra-
tion of MT, which will help to alleviate not only the side effects 
associated with the use of high dose oral therapy of 6 g per day 
but also circumventing the variable oral absorption resulting in 
more predictable therapeutic plasma concentration and better 
Macromol. Biosci. 2020, 20, 1900178
Figure 4. Cell viability of A-pBuOx-A (P2) in a) NCI-H295 and b) HepG2 
cell line by WST1 assay and c) NCI-H295 cell line by CellTiter Glo assay 
after 6 h (white) and 24 h (black) incubation. Experiments were per-
formed as duplicate (in case of WST1 assay) and as single experiment for 
the CellTiter Glo assay with n = 8 technical replicates. Data is expressed 
as means ± standard deviation.
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pharmacokinetic profile. However, the safety and tolerability of 
this injectable formulation remain to be demonstrated.
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Supporting Information is available from the Wiley Online Library or 
from the author.
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